⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for venetoclax

Every month we try and update this database with for venetoclax cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance MutationsNCT03513562
Chronic Lymphoc...
Ibrutinib Resis...
Ibrutinib
Laboratory Biom...
Venetoclax
18 Years - Ohio State University Comprehensive Cancer Center
Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous LeukemiaNCT02689440
Chronic Phase C...
Philadelphia Ch...
Dasatinib
Laboratory Biom...
Venetoclax
18 Years - M.D. Anderson Cancer Center
A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess BlastsNCT05365035
Myelodysplastic...
Myeloproliferat...
Cladribine
Cytarabine
Venetoclax
Azacitidine
18 Years - M.D. Anderson Cancer Center
Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell TransplantNCT05799079
Recurrent Acute...
Venetoclax
Decitabine
Cedazuridine
Bone Marrow Asp...
Biospecimen Col...
18 Years - Vanderbilt-Ingram Cancer Center
Venetoclax and Vincristine Liposomal in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic LeukemiaNCT03504644
B Acute Lymphob...
Lymphoblasts 5 ...
Recurrent Adult...
Recurrent Child...
Refractory Acut...
T Acute Lymphob...
Laboratory Biom...
Venetoclax
Vincristine Lip...
18 Years - Eastern Cooperative Oncology Group
Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in RemissionNCT05010772
Acute Myeloid L...
Decitabine and ...
Enasidenib
Gilteritinib
Ivosidenib
Venetoclax
18 Years - M.D. Anderson Cancer Center
Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)NCT06210750
T Acute Lymphob...
T Lymphoblastic...
Biospecimen Col...
Bone Marrow Asp...
Bone Marrow Bio...
Calaspargase Pe...
Computed Tomogr...
Cyclophosphamid...
Cytarabine
Daunorubicin
Dexamethasone
Doxorubicin
Echocardiograph...
Lumbar Puncture
Mercaptopurine
Methotrexate
Multigated Acqu...
Navitoclax
Nelarabine
Pegaspargase
Positron Emissi...
Thioguanine
Venetoclax
Vincristine
X-Ray Imaging
18 Years - 60 YearsNational Cancer Institute (NCI)
Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant SettingNCT04128501
Acute Bilineal ...
Acute Biphenoty...
Acute Myeloid L...
Mixed Phenotype...
T Acute Lymphob...
Therapy-Related...
Azacitidine
Venetoclax
18 Years - 75 YearsM.D. Anderson Cancer Center
Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.NCT03217838
Acute Myeloid L...
AZD2811
Azacitidine
Venetoclax
18 Years - 130 YearsAstraZeneca
A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic LeukemiaNCT05268003
Acute Lymphobla...
Leukemia
Ponatinib
Venetoclax
Mini-hyper CVD
12 Years - M.D. Anderson Cancer Center
Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)NCT04608318
Chronic Lymphoi...
Ibrutinib
Venetoclax
Obinutuzumab
18 Years - German CLL Study Group
Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid LeukemiaNCT04964505
Acute Myeloid L...
Azacitidine
Uproleselan
Venetoclax
18 Years - University of California, Davis
Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous LeukemiaNCT04172844
Acute Myelogeno...
Azacitidine
Venetoclax
Pevonedistat
18 Years - Medical College of Wisconsin
Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113NCT04070768
Acute Myeloid L...
Gemtuzumab Ozog...
Venetoclax
18 Years - Big Ten Cancer Research Consortium
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)NCT06428019
Chronic Lymphoc...
Venetoclax
Acalabrutinib
Obinutuzumab
18 Years - AbbVie
A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer TreatmentNCT02951117
Multiple Myelom...
Venetoclax
ABBV-838
Dexamethasone
18 Years - 99 YearsAbbVie
A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML)NCT04509622
Acute Myeloid L...
Venetoclax
Cytarabine
18 Years - AbbVie
Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell LymphomaNCT05861050
Blastoid Varian...
Mantle Cell Lym...
Pleomorphic Var...
Biopsy
Biospecimen Col...
Bone Marrow Bio...
Computed Tomogr...
Glofitamab
Lenalidomide
Obinutuzumab
Positron Emissi...
Venetoclax
18 Years - 80 YearsCity of Hope Medical Center
Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic LeukemiaNCT03609593
Chronic Lymphoc...
Bendamustine
Venetoclax
Rituximab
18 Years - 99 YearsColumbia University
Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid LeukemiaNCT04898894
Acute Leukemia ...
Acute Myeloid L...
Refractory Acut...
Refractory Acut...
Venetoclax
Selinexor
Cytarabine
Fludarabine
Filgrastim
Methotrexate
methotrexate/hy...
2 Years - 30 YearsSt. Jude Children's Research Hospital
Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96NCT04589728
Acute Myeloid L...
Venetoclax plus...
18 Years - Gruppo Italiano Malattie EMatologiche dell'Adulto
A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid LeukemiaNCT05520567
Acute Myeloid L...
FLT3-mutated Ac...
Gilteritinib
Venetoclax
Azacitidine
18 Years - Astellas Pharma Inc
A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)NCT04790903
Lymphoma, Large...
Venetoclax
Polatuzumab Ved...
Rituximab
Cyclophosphamid...
Doxorubicin
Prednisone
18 Years - Hoffmann-La Roche
Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell LymphomaNCT03534180
Anaplastic Larg...
Recurrent Matur...
Refractory Matu...
Laboratory Biom...
Romidepsin
Venetoclax
18 Years - City of Hope Medical Center
Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell LymphomasNCT03036904
Diffuse Large B...
High Grade B-Ce...
Venetoclax
Rituximab
Etoposide
Vincristine Sul...
Cyclophosphamid...
Prednisone
Doxorubicin Hyd...
18 Years - 80 YearsWeill Medical College of Cornell University
Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell LymphomasNCT03036904
Diffuse Large B...
High Grade B-Ce...
Venetoclax
Rituximab
Etoposide
Vincristine Sul...
Cyclophosphamid...
Prednisone
Doxorubicin Hyd...
18 Years - 80 YearsWeill Medical College of Cornell University
A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast CancerNCT04298918
Breast Cancer
Placebo
Venetoclax
Trastuzumab emt...
18 Years - Hoffmann-La Roche
Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or RefractoryNCT03969446
Acute Myeloid L...
Myelodysplastic...
Recurrent Acute...
Recurrent Myelo...
Refractory Acut...
Refractory Myel...
Decitabine
Pembrolizumab
Venetoclax
18 Years - City of Hope Medical Center
Intensive Therapy Combined With Venetoclax for Adult Acute Myeloid LeukemiaNCT05356169
Acute Myeloid L...
with or without...
18 Years - 65 YearsInstitute of Hematology & Blood Diseases Hospital, China
A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid LeukemiaNCT05736965
AML, Adult
Selinexor
Azacitidine
Venetoclax
18 Years - Shanghai Tong Ren Hospital
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid LeukemiaNCT03629171
Recurrent Acute...
Refractory Acut...
Liposome-encaps...
Venetoclax
18 Years - M.D. Anderson Cancer Center
Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)NCT03801525
Chronic Lymphoc...
Small Lymphocyt...
Ublituximab
Umbralisib
Venetoclax
18 Years - TG Therapeutics, Inc.
A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.NCT05155709
Acute Myeloid L...
siremadlin
venetoclax
azacitidine
18 Years - 99 YearsNovartis
Expanded Access to NavitoclaxNCT03592576
Myelofibrosis
Acute Lymphocyt...
Lymphoblastic L...
Navitoclax
Venetoclax
4 Years - AbbVie
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy in Switzerland and Austria Receiving Oral Venetoclax TabletsNCT05215639
Acute Myeloid L...
18 Years - AbbVie
Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic LeukemiaNCT06085638
Chronic Myelomo...
Azacitidine
Tamibarotene
Venetoclax
18 Years - M.D. Anderson Cancer Center
Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)NCT02203773
Acute Myelogeno...
Myelogenous Leu...
Treatment Naive...
Posaconazole
ABT-199
Decitabine
Azacitidine
60 Years - AbbVie
Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid LeukemiaNCT05362942
Relapsed Acute ...
Refractory Acut...
Minimal Residua...
Venetoclax, Dec...
18 Years - Beijing 302 Hospital
A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple MyelomaNCT03314181
Multiple Myelom...
Dexamethasone
Daratumumab
Venetoclax
Bortezomib
18 Years - AbbVie
Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell LymphomaNCT04659044
Recurrent B-Cel...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Refractory B-Ce...
Refractory Grad...
Refractory Grad...
Refractory Grad...
Refractory Mant...
Refractory Marg...
Refractory Smal...
Polatuzumab Ved...
Rituximab
Rituximab and H...
Venetoclax
18 Years - Academic and Community Cancer Research United
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in CanadaNCT05424562
Acute Myeloid L...
18 Years - AbbVie
Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative DiseaseNCT04146038
Acute Myeloid L...
Chronic Myelomo...
Myeloblasts 10 ...
Myelodysplastic...
Myeloproliferat...
Recurrent Acute...
Refractory Acut...
Secondary Acute...
Azacitidine
Decitabine
Salsalate
Venetoclax
18 Years - Rutgers, The State University of New Jersey
Safe Accelerated Venetoclax Escalation in CLLNCT04843904
Chronic Lymphoc...
Small Lymphocyt...
Venetoclax
Obinutuzumab
Rituximab
18 Years - Dana-Farber Cancer Institute
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell LymphomaNCT04739813
Lymphoma
Non-Hodgkin Lym...
Diffuse Large B...
Burkitt Lymphom...
obinutuzumab
prednisone
Revlimid
Polatuzumab
ibrutinib
venetoclax
18 Years - 120 YearsNational Institutes of Health Clinical Center (CC)
A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic LeukemiaNCT05268003
Acute Lymphobla...
Leukemia
Ponatinib
Venetoclax
Mini-hyper CVD
12 Years - M.D. Anderson Cancer Center
Safe Accelerated Venetoclax Escalation in CLLNCT04843904
Chronic Lymphoc...
Small Lymphocyt...
Venetoclax
Obinutuzumab
Rituximab
18 Years - Dana-Farber Cancer Institute
Venetoclax + Azacitidine vs. Induction Chemotherapy in AMLNCT04801797
Acute Myeloid L...
Cytarabine
Idarubicin
Daunorubicin
Liposomal dauno...
Venetoclax
Azacitidine
18 Years - Massachusetts General Hospital
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)NCT05105841
Chronic Lymphoc...
Small Lymphocyt...
Venetoclax
Ibrutinib
Obinutuzumab
20 Years - AbbVie
A Study Of The Selective PKC-β Inhibitor MS- 553NCT03492125
Chronic Lymphoc...
Small Lymphocyt...
Aggressive Lymp...
MS-553
MS-553
acalabrutinib
venetoclax
Rituximab
obinutuzumab
18 Years - MingSight Pharmaceuticals, Inc
Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life SettingNCT03342144
Chronic Lymphoc...
18 Years - AbbVie
CIML NK Cells With Venetoclax for AMLNCT06152809
Acute Myeloid L...
Acute Myeloid L...
Leukemia
Leukemia, Myelo...
Cytokine-Induce...
Interleukin-2
Venetoclax
18 Years - Dana-Farber Cancer Institute
A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets ± Intravenously (IV) Infused Rituximab in Routine Clinical Practice in JapanNCT06362044
Chronic Lymphoc...
18 Years - AbbVie
Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple MyelomaNCT06042725
Multiple Myelom...
Biospecimen Col...
Bone Marrow Asp...
Bone Marrow Bio...
Chest Radiograp...
Computed Tomogr...
Daratumumab
Dexamethasone
Lenalidomide
Low Dose Comput...
Magnetic Resona...
Positron Emissi...
Venetoclax
X-Ray Imaging
Questionnaire A...
18 Years - Mayo Clinic
A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and RevumenibNCT06284486
Acute Myeloid L...
Venetoclax
Revumenib
12 Years - M.D. Anderson Cancer Center
A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6NCT03255096
Diffuse Large B...
High-Grade B-ce...
RO6870810
Venetoclax
Rituximab
18 Years - Hoffmann-La Roche
Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic SyndromeNCT04487106
Recurrent Acute...
Recurrent Chron...
Recurrent Myelo...
Refractory Acut...
Refractory Chro...
Refractory Myel...
Azacitidine
Trametinib
Venetoclax
18 Years - M.D. Anderson Cancer Center
Venetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin LymphomaNCT03713580
Non-hodgkin Lym...
Venetoclax
18 Years - Case Comprehensive Cancer Center
Study to Evaluate CCS1477 in Haematological MalignanciesNCT04068597
Haematological ...
Acute Myeloid L...
Non Hodgkin Lym...
Multiple Myelom...
Higher-risk Mye...
Peripheral T Ce...
CCS1477
Pomalidomide
Dexamethasone
Azacitidine
Venetoclax
18 Years - CellCentric Ltd.
Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)NCT03801525
Chronic Lymphoc...
Small Lymphocyt...
Ublituximab
Umbralisib
Venetoclax
18 Years - TG Therapeutics, Inc.
Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)NCT04657081
Acute Myeloid L...
Decitabine and ...
Venetoclax
18 Years - Astex Pharmaceuticals, Inc.
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Oral Venetoclax Tablets in Combination With Subcutaneously (SC) or Intravenously (IV) Injected Azacitidine in ColombiaNCT05587049
Acute Myeloid L...
18 Years - AbbVie
Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell TransplantationNCT05005299
Leukemia, Myelo...
Leukemia, Lymph...
Leukemia, Lymph...
Myelodysplastic...
Non-hodgkin Lym...
Plasma Cell Mye...
Venetoclax
Fludarabine
Cyclophosphamid...
18 Years - 75 YearsMelbourne Health
Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants of Any Age With Acute Myeloid LeukemiaNCT04813263
Acute Myeloid L...
- AbbVie
A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose TherapyNCT03785184
Multiple Myelom...
venetoclax
lenalidomide
dexamethasone
18 Years - AbbVie
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin LymphomaNCT05283720
Non-Hodgkin Lym...
Epcoritamab
Lenalidomide
Ibrutinib
Rituximab
Cyclophosphamid...
Doxorubicin Hyd...
Prednisone
Polatuzumab Ved...
Venetoclax
CC-99282
18 Years - Genmab
Study of Venetoclax in Combination With Azacytidine in AML Patients Selected Using Ex Vivo Drug Sensitivity ScreeningNCT04267081
Acute Myeloid L...
Venetoclax
18 Years - 100 YearsHelsinki University Central Hospital
Personalized Medication Software for BCL-2 Inhibitor in AML Patients Using Machine Learning and GenomicsNCT06295029
Acute Myeloid L...
18 Years - The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaNCT02992522
B-Cell Lymphoma...
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3a Follic...
Recurrent Burki...
Recurrent Diffu...
Recurrent Folli...
Recurrent Margi...
Refractory Burk...
Refractory Diff...
Refractory Foll...
Transformed Rec...
B-Cell
Lenalidomide
Obinutuzumab
Venetoclax
18 Years - Ohio State University Comprehensive Cancer Center
Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaNCT02992522
B-Cell Lymphoma...
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3a Follic...
Recurrent Burki...
Recurrent Diffu...
Recurrent Folli...
Recurrent Margi...
Refractory Burk...
Refractory Diff...
Refractory Foll...
Transformed Rec...
B-Cell
Lenalidomide
Obinutuzumab
Venetoclax
18 Years - Ohio State University Comprehensive Cancer Center
Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple MyelomaNCT03399539
Recurrent Plasm...
t(11;14)
Dexamethasone
Ixazomib Citrat...
Laboratory Biom...
Venetoclax
18 Years - Mayo Clinic
A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLLNCT05197192
Chronic Lymphoc...
Obinutuzumab
Venetoclax
Acalabrutinib
18 Years - 120 YearsGerman CLL Study Group
Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast CancerNCT03900884
Breast Neoplasm...
Venetoclax
Palbociclib
Letrozole
18 Years - Peter MacCallum Cancer Centre, Australia
A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)NCT06191978
Acute Myeloid L...
ASTX727
Venetoclax
2 Years - 18 YearsM.D. Anderson Cancer Center
A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)NCT01671904
Chronic Lymphoc...
Bendamustine
Obinutuzumab
Rituximab
Venetoclax
18 Years - Genentech, Inc.
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid TumorsNCT04029688
Acute Myeloid L...
Acute Lymphobla...
Neuroblastoma
Solid Tumors
Idasanutlin
Venetoclax
Cyclophosphamid...
Topotecan
Fludarabine
Cytarabine
Intrathecal Che...
0 Years - 30 YearsHoffmann-La Roche
Venetoclax After TKI to Target Persisting Stem Cells in CMLNCT05701215
Chronic Myeloid...
Venetoclax
18 Years - University of Jena
This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With VenetoclaxNCT03343678
Leukemia, Lymph...
Venetoclax
BI 836826
18 Years - Boehringer Ingelheim
ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeNCT05010122
Acute Myeloid L...
Myelodysplastic...
Recurrent Acute...
Refractory Acut...
Decitabine and ...
Gilteritinib
Venetoclax
18 Years - M.D. Anderson Cancer Center
BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid LeukemiaNCT04284787
Acute Myeloid L...
Acute Myeloid L...
Acute Myeloid L...
Secondary Acute...
Azacitidine
Biopsy
Biospecimen Col...
Bone Marrow Asp...
Bone Marrow Bio...
Pembrolizumab
Venetoclax
60 Years - National Cancer Institute (NCI)
Venetoclax Basket Trial for High Risk Hematologic MalignanciesNCT05292664
Myelodysplastic...
Myelodysplastic...
Myelodysplastic...
Treatment-Relat...
Therapy-Related...
Acute Lymphobla...
Acute Lymphobla...
Lymphoblastic L...
Lymphoblastic L...
Acute Leukemia ...
Acute Leukemia ...
Venetoclax
Azacitidine
Cytarabine
Methotrexate
Hydrocortisone
Leucovorin
Dexamethasone
Vincristine
Doxorubicin
Dexrazoxane
Calaspargase Pe...
Erwinia asparag...
1 Year - 40 YearsDana-Farber Cancer Institute
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: